CANF (Can-Fite BioPharma, Ltd.) חוב לטווח ארוך

Can-Fite BioPharma is developing a global network through licensing agreements with distributors to promote treatments for liver cancer and psoriasis. The current patient base in Europe is expanding through Piclidenoson trials, while FDA approval will enable entry into the mass market. The daily price action, where the indicator stands at 0.00, confirms the impact of strict FDA oversight and the patent protection of the drugs.

This indicator aggregates the issuer's multi-year credit obligations, allowing for an assessment of financial leverage stability and default risk through the lens of long-term debt load. By analyzing the firm's long-term borrowed capital, investors can track the borrowing dynamics required by Can-Fite BioPharma (CANF) to finance costly research and development in oncology and inflammatory liver disease therapies.